Avalon Investment & Advisory’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-15,044
| Closed | -$671K | – | 359 |
|
|
2021
Q1 | $671K | Sell |
15,044
-316,365
| -95% | -$14.4M | 0.02% | 265 |
|
|
2020
Q4 | $15.2M | Sell |
331,409
-114,386
| -26% | -$5.25M | 0.31% | 101 |
|
|
2020
Q3 | $21M | Sell |
445,795
-25,991
| -6% | -$1.3M | 0.47% | 65 |
|
|
2020
Q2 | $24.1M | Sell |
471,786
-33,504
| -7% | -$1.72M | 0.55% | 55 |
|
|
2020
Q1 | $23.9M | Buy |
505,290
+39,008
| +8% | +$2.08M | 0.61% | 49 |
|
|
2019
Q4 | $27.4M | Buy |
466,282
+11,111
| +2% | +$618K | 0.56% | 55 |
|
|
2019
Q3 | $24.3M | Buy |
455,171
+8,175
| +2% | +$421K | 0.54% | 61 |
|
|
2019
Q2 | $22.4M | Sell |
446,996
-2,840
| -0.6% | -$143K | 0.5% | 64 |
|
|
2019
Q1 | $23.5M | Buy |
449,836
+20,878
| +5% | +$1.04M | 0.53% | 57 |
|
|
2018
Q4 | $20.5M | Buy |
428,958
+5,573
| +1% | +$274K | 0.53% | 53 |
|
|
2018
Q3 | $21.3M | Buy |
423,385
+61,744
| +17% | +$3.14M | 0.6% | 50 |
|
|
2018
Q2 | $18.2M | Buy |
361,641
+329,723
| +1,033% | +$16.6M | 0.54% | 69 |
|
|
2018
Q1 | $1.56M | Buy |
31,918
+4,114
| +15% | +$192K | 0.05% | 230 |
|
|
2017
Q4 | $1.23M | Sell |
27,804
-250,292
| -90% | -$11.6M | 0.04% | 240 |
|
|
2017
Q3 | $14.1M | Buy |
278,096
+7,890
| +3% | +$400K | 0.45% | 79 |
|
|
2017
Q2 | $14.6M | Buy |
270,206
+872
| +0.3% | +$46.5K | 0.48% | 69 |
|
|
2017
Q1 | $14.2M | Sell |
269,334
-12,711
| -5% | -$645K | 0.49% | 70 |
|
|
2016
Q4 | $13.6M | Sell |
282,045
-242,694
| -46% | -$12M | 0.49% | 67 |
|
|
2016
Q3 | $28.3M | Buy |
524,739
+64,483
| +14% | +$3.54M | 1.06% | 26 |
|
|
2016
Q2 | $24.9M | Buy |
460,256
+437,174
| +1,894% | +$23M | 0.96% | 35 |
|
|
2016
Q1 | $1.17M | Buy |
23,082
+11,928
| +107% | +$594K | 0.05% | 147 |
|
|
2015
Q4 | $563K | Buy |
11,154
+2
| +0% | +$102 | 0.02% | 195 |
|
|
2015
Q3 | $536K | Sell |
11,152
-1,198
| -10% | -$62.4K | 0.02% | 196 |
|
|
2015
Q2 | $643K | Buy |
12,350
+2,458
| +25% | +$138K | 0.03% | 177 |
|
|
2015
Q1 | $571K | Sell |
9,892
-538
| -5% | -$30.8K | 0.02% | 154 |
|
|
2014
Q4 | $557K | Buy |
10,430
+111
| +1% | +$6.21K | 0.03% | 137 |
|
|
2014
Q3 | $593K | Sell |
10,319
-296,683
| -97% | -$18.2M | 0.03% | 141 |
|
|
2014
Q2 | $20.5M | Buy |
307,002
+107,405
| +54% | +$7.27M | 1.04% | 27 |
|
|
2014
Q1 | $13.3M | Buy |
199,597
+1,855
| +0.9% | +$125K | 0.74% | 46 |
|
|
2013
Q4 | $13.2M | Buy |
197,742
+3,257
| +2% | +$211K | 0.74% | 47 |
|
|
2013
Q3 | $12.2M | Buy |
194,485
+996
| +0.5% | +$64.1K | 0.79% | 43 |
|
|
2013
Q2 | $12.1M | Buy |
+193,489
| New | +$12.3M | 0.72% | 47 |
|
Other funds holding GSK
BCIM
Avalon Investment & Advisory's GSK Position: Q2 2021 in Review
Avalon Investment & Advisory sold out of GSK (GSK) in Q2 2021, closing a stake of 15,044 shares — an estimated $671K sold.
Avalon Investment & Advisory first reported a position in GSK in Q2 2013 and held it in 32 quarters. The position peaked at $28.3M in Q3 2016. 798 funds tracked by Wall St. Rank hold GSK as of Q2 2021.
- Avalon Investment & Advisory reported no remaining GSK position as of Q2 2021 after selling out during the quarter.
- Avalon Investment & Advisory sold 15,044 GSK shares in Q2 2021, an estimated $671K.
- Avalon Investment & Advisory first reported a position in GSK in Q2 2013 and held it in 32 quarters.
- Avalon Investment & Advisory's GSK position peaked at $28.3M in Q3 2016.
- 798 funds tracked by Wall St. Rank held GSK as of Q2 2021.
Based on Avalon Investment & Advisory's 13F filing for Q2 2021, filed 29 Jul 2021.